Sensing a Healthier Future with Sustainable Nanomaterials and Biosensors

FHS
May 16, 2024
3:59 pm

In this interview conducted at Pittcon 2024 in San Diego, we spoke to this year’s Keynote Speaker Professor Omowunmi (Wunmi) Sadik about how sustainable nanomaterials are transforming human health.

CSL’s ‘big’ post-heart attack drug fails in Phase III trial

Share this article CSL’s AEGIS-II study for its MI drug CSL112 enrolled 18,200 participants across 850 sites worldwide. Image Credit: viewimage / Shutterstock. Australian CSL

February 12, 2024

Indivior axes schizophrenia drug and shrinks revenue guidance

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 13, 2024

Cardiovascular risks post-COVID-19 vaccination: Key findings

Researchers explore the risks of cardiovascular and cerebrovascular events following vaccination against the COVID-19.

October 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.